Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B

Background: Visceral leishmaniasis (VL), a potentially fatal disease, is most prevalent in the Indian subcontinent, East Africa and South America. Since the conventional antileishmanial drugs have many limitations we evaluated a new ergosterol rich liposomal amphotericin B formulation, KALSOME (TM) 10 for its leishmanicidal efficacy, tolerability and immunomodulatory activity. Methods: Normal healthy mice were treated with 3.5 mg/kg single and 7.5 mg/kg single and double doses of KALSOME (TM) 10. Liver and kidney function tests were performed fourteen days after treatment. Next, normal mice were infected with Leishmania donovani amastigotes. Two months post infection they were treated with the above mentioned doses of KALSOME (TM) 10 and sacrificed one month after treatment for estimation of parasite burden in the liver and spleen by Limiting Dilution Assay. Leishmanial antigen stimulated splenocyte culture supernatants were collected for cytokine detection through ELISA. Flow cytometric studies were performed on normal animals treated with KALSOME (TM) 10, Amphotericin B (AmB) and AmBiosome to compare their immunomodulatory activities. Results: The drug was found to induce no hepato- or nephrotoxicities at the studied doses. Moreover, at all doses, it led to significant reduction in parasite burden in two month infected BALB/c mice, with 7.5 mg/kg double dose resulting in almost complete clearance of parasites from both liver and spleen. Interestingly, the drug at 7.5 mg/kg double dose could almost completely inhibit the secretion of disease promoting cytokines, IL-10 and TGF beta, and significantly elevate the levels of IFN gamma and IL-12, cytokines required for control of the disease. Mice treated with KALSOME (TM) 10 showed elevated levels of IFN gamma and suppressed IL-10 secretion from both CD4(+) and CD8(+) subsets of T cells, as well as from culture supernatants of splenocytes, compared to that of normal, AmB and AmBisome treated animals. Conclusions: Treatment of infected mice with 7.5 mg/kg double dose of KALSOME (TM) 10 was safe and effective in clearing the parasites from the sites of infection. The drug maintains the inherent immunomodulatory activities of AmB by effectively suppressing disease promoting cytokines IL-10 and TGF beta, thereby boosting IL-12 and IFN gamma levels. This emphasizes KALSOME (TM) 10 as a promising drug alternative for lifelong protection from VL.